Preferred panel for detecting glomerular basement membrane (GBM) antibodies in suspected or established anti-GBM disease. If positive, may be useful for monitoring treatment response.
Semi-Quantitative Multiplex Bead Assay/Qualitative Indirect Fluorescent Antibody
New York DOH Approval Status
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
When present, IgG antibody to glomerular basement membrane (GBM) antigen detected by either indirect fluorescent antibody (IFA) or multiplex bead assay helps support a diagnosis of Goodpasture syndrome. However, the combined result of both assays performed during initial evaluation improves the diagnostic sensitivity for disease. A positive result in one or both assays should be confirmed by renal biopsy.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0049191||GBM Antibody, IgG by IFA||29994-1|
|0051000||GBM Ab, IgG by Multiplex Bead Assay||44446-3|
- Anti-GBM Antibody-IgG
- Antiglomerular Basement Membrane Antibody-IgG
- Basement Membrane Antibody
- Basement Membrane, Glomerular Antibody
- GBM Antibody
- Glomerular Anti-Basement Membrane